XTRA:MF6

Stock Analysis Report

Executive Summary

MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland.

Snowflake

Fundamentals

Exceptional growth potential and good value.

Share Price & News

How has MagForce's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.3%

MF6

4.2%

DE Medical Equipment

1.7%

DE Market


1 Year Return

-22.8%

MF6

22.1%

DE Medical Equipment

7.2%

DE Market

Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned 22.1% over the past year.

Return vs Market: MF6 underperformed the German Market which returned 7.2% over the past year.


Shareholder returns

MF6IndustryMarket
7 Day11.3%4.2%1.7%
30 Day4.0%2.9%2.4%
90 Day-6.1%1.4%2.3%
1 Year-22.8%-22.8%24.1%22.1%10.6%7.2%
3 Year8.7%8.7%113.3%107.7%18.4%8.1%
5 Year-14.3%-14.3%292.1%272.3%42.3%22.9%

Price Volatility Vs. Market

How volatile is MagForce's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MagForce undervalued compared to its fair value and its price relative to the market?

48.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MF6 (€4.63) is trading below our estimate of fair value (€9.07)

Significantly Below Fair Value: MF6 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MF6 is good value based on its PE Ratio (28.1x) compared to the Medical Equipment industry average (33.3x).

PE vs Market: MF6 is poor value based on its PE Ratio (28.1x) compared to the German market (19x).


Price to Earnings Growth Ratio

PEG Ratio: MF6 is good value based on its PEG Ratio (0.5x)


Price to Book Ratio

PB vs Industry: MF6 is overvalued based on its PB Ratio (6.7x) compared to the DE Medical Equipment industry average (5.9x).


Next Steps

Future Growth

How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

57.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MF6's forecast earnings growth (57.3% per year) is above the savings rate (0.2%).

Earnings vs Market: MF6's earnings (57.3% per year) are forecast to grow faster than the German market (12.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MF6's revenue (56.1% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: MF6's revenue (56.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MF6's Return on Equity is forecast to be very high in 3 years time (46.9%).


Next Steps

Past Performance

How has MagForce performed over the past 5 years?

-14.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MF6 has become profitable over the past 5 years, growing earnings by -14.7% per year.

Accelerating Growth: MF6 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MF6 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.4%).


Return on Equity

High ROE: MF6's Return on Equity (24%) is considered high.


Return on Assets

ROA vs Industry: MF6 has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: MF6 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is MagForce's financial position?


Financial Position Analysis

Short Term Liabilities: MF6's short term assets (€2.6M) exceeds its short term liabilities (€1.7M)

Long Term Liabilities: MF6's short term assets (2.6M) do not cover its long term liabilities (17.3M)


Debt to Equity History and Analysis

Debt Level: MF6's debt to equity ratio (87.4%) is considered high

Reducing Debt: Insufficient data to determine if MF6's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if MF6's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if MF6's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: MF6 has a low level of unsold assets or inventory.

Debt Coverage by Assets: MF6's debt is not covered by short term assets (assets are 0.2x debt).


Next Steps

Dividend

What is MagForce's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.4%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MF6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MF6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MF6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MF6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MF6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of MagForce's salary, the management and board of directors tenure and is there insider trading?

7.0yrs

Average management tenure


CEO

Ben Lipps (79yo)

6.1yrs

Tenure

0

Dr. Benjamin J. Lipps, also known as Ben, has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG since September 1, 2013. Dr. Lipps served as the Chief Executive Officer a ...


Management Age and Tenure

7.0yrs

Average Tenure

62yo

Average Age

Experienced Management: MF6's management team is seasoned and experienced (7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Andreas Jordan (60yo)

    Founder & Advisor

    • Tenure: 0yrs
  • Ben Lipps (79yo)

    Chairman of the Management Board & CEO

    • Tenure: 6.1yrs
  • Christian Von Volkmann (48yo)

    CFO & Member of Management Board

    • Tenure: 7yrs
  • Hans Hutt

    Medical Consultant

    • Tenure: 8.9yrs
  • Solveig Salomon

    VP of Marketing & Sales and European Commercial Director

    • Tenure: 0yrs
  • Barbara Frankenberg

    Vice President of Communications & Investor Relations

    • Tenure: 3.6yrs
  • Hoda Tawfik (64yo)

    Chief Medical Officer & Member of Management Board

    • Tenure: 7yrs

Board Members

  • Norbert Neef (52yo)

    Chairman of the Supervisory Board

    • Tenure: 0yrs
  • Wiebke Rösler

    Member of the Supervisory Board

    • Tenure: 5.2yrs
  • Klemens Hallmann (43yo)

    Deputy Chairman of Supervisory Board

    • Tenure: 2.2yrs

Company Information

MagForce AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MagForce AG
  • Ticker: MF6
  • Exchange: XTRA
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €127.974m
  • Shares outstanding: 27.64m
  • Website: https://www.magforce.com

Number of Employees


Location

  • MagForce AG
  • Max-Planck-Strasse 3
  • Berlin
  • Berlin
  • 12489
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MF6DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2007
MF6XTRA (XETRA Trading Platform)YesCommon StockDEEURSep 2007
MGFR.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2007
0W10LSE (London Stock Exchange)YesCommon StockGBEURSep 2007

Biography

MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing su ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 21:01
End of Day Share Price2019/10/23 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.